Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.00 USD
Change Today +0.22 / 3.24%
Volume 272.3K
CYTK On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cytokinetics inc (CYTK) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/17/15 - $8.61
52 Week Low
10/13/14 - $3.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYTOKINETICS INC (CYTK)

cytokinetics inc (CYTK) Related Businessweek News

No Related Businessweek News Found

cytokinetics inc (CYTK) Details

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is involved in developing Tirasemtiv, a fast skeletal troponin activator that is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107 that is in Phase I for the treatment of spinal muscle atrophy; and Omecamtiv mecarbil, which is in Phase II clinical trials for the potential treatment of heart failure. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to advance novel therapies for diseases and medical conditions associated with muscle weakness. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

92 Employees
Last Reported Date: 03/6/15
Founded in 1997

cytokinetics inc (CYTK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $555.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $401.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $388.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $384.6K
Senior Vice President of Human Resources
Total Annual Compensation: $285.0K
Compensation as of Fiscal Year 2014.

cytokinetics inc (CYTK) Key Developments

Cytokinetics, Incorporated Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year 2015

Cytokinetics, Incorporated reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. Revenues for the second quarter of 2015 were $6.5 million, compared to $7.8 million during the same period in 2014. Operating loss was $10,589,000 compared to $8,407,000 a year ago. Net loss was $10,551,000 or $0.27 per diluted share compared to $8,374,000 or $0.23 per diluted share a year ago. Revenues for the six months ended June 30, 2015 were $11.0 million, compared to $15.8 million for the same period in 2014. The net loss for the six months ended June 30, 2015, was $19.4 million, or $0.50 per basic and diluted share, compared to a net loss of $17.1 million, or $0.49 per basic and diluted share, for the same period in 2014. Operating loss was $19,498,000 compared to $17,177,000 a year ago. For the year 2015, the company anticipates cash revenue to be in the range of $44 to $47 million, cash R&D expenses in the range of $58 to $61 million, and cash G&A expenses to be in the range of $18 to $21 million. This guidance includes the $30 million upfront payment from Astellas that will be deferred and recognized over a two year period ending in 2016 under generally accepted accounting principles. This guidance excludes the $15 million milestone payment earned in 2014 from Astellas and an estimated $3.6 million in non-cash related operating expenses primarily related to stock compensation.

Cytokinetics, Incorporated to Report Q2, 2015 Results on Jul 29, 2015

Cytokinetics, Incorporated announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Jul 29, 2015

Cytokinetics, Incorporated, Q2 2015 Earnings Call, Jul 29, 2015

Cytokinetics, Incorporated, Q2 2015 Earnings Call, Jul 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTK:US $7.00 USD +0.22

CYTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.76 USD 0.00
CTI BioPharma Corp $1.60 USD +0.03
Curis Inc $2.59 USD +0.09
Evotec AG €3.77 EUR -0.029
GlaxoSmithKline SAE £9.99 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOKINETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at